Attendee search 

There are multiple suppliers and distributors of the organ preservation solutions developed by Drs. Belzer and Southard at the University of Wisconsin. All patents on the formulations used in Belzer UW® Solutions (cold storage and machine perfusion) expired in 2006. Bridge to Life has an exclusive trademark license from the Wisconsin Alumni Research Foundation (WARF) for the trademark Belzer UW®.

In fact, WARF holds an equity position in Bridge to Life Ltd., a WARF startup company. We proudly honor the name of Dr. Belzer and the institution that developed the UW organ preservation solution, which is still the “gold standard” in organ preservation.

Founded by current CEO Justin Andrew Marsh. Mr. Marsh, a former microchip engineer and automation control contractor for companies such as Motorola, Intel and Medtronic, developed the company as a majority investor. The company originally specialized in the importation of enzymes and other raw materials.  As a majority of today’s current pharmaceuticals are designed to mimic enzymes, the company strives to develop and discover new medicines through enzyme research and development.

In 2003 Justin Andrew Marsh bought out his minority investors and Arthur Andrew Medical was formed. With the collaboration of well-known enzymologists and best-in-class materials, Arthur Andrew Medical began to create finished products under its own brand-name. In 2003, Neprinol, the world’s most potent systemic enzyme was born. Arthur Andrew's mission is to be the leader in the development of systemic enzyme products in the enzyme-pharma and supplement industry. While other companies develop products based on market trends and fads, Arthur Andrew Medical only adopts products with ingredients that have extensive clinical research for safety and efficacy.

Welcome to the Center for Human Reproduction (CHR), a leading fertility center located in New York City. CHR is known as a “fertility center of last resort,” primarily serving patients who have previously failed treatments elsewhere. Among CHR’s areas of special expertise are treatments of “older” ovaries, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.

Specialties:  Oncology, Cancer Research, Cell Biology

NYU School of Medicine is one of the nation’s preeminent academic institutions. For more than 150 years, we have trained thousands of physician-scientists who have helped to shape the course of medical history and enrich the lives of countless people. Through medical education, scientific research, and patient care, we continue to demonstrate our deep, abiding commitment to improving the human condition.

The percentage of NYU graduates who are members of medical school faculties is among the highest in the nation. For most of them, an invaluable part of that training was their service at Bellevue Hospital, one of the nation’s finest municipal hospitals, where NYU physicians have provided clinical and emergency care to
New York City’s poor and immigrant populations for more than a century.

As part of a “biomedical corridor” extending from 23rd to 34th Streets along Manhattan’s East River Drive, our institution is guided by the promise of “translational medicine,” in which scientific discoveries are urgently translated into innovative treatments for patients. To create an environment worthy of rapid medical advances, we are constructing new research and clinical facilities. These state-of-the-art facilities will serve as the home for our physician-scientists who are the intellectual foundation of the School. In addition, we are recruiting a new generation of scholars and teachers who have established national and international reputations. And we are admitting some of the nation’s best and brightest students, many of whom will become tomorrow’s leaders in the medical profession.

Your focus and ours is whether NYU is the right place to pursue your medical education. We hope that this website captures the spirit of the educational enterprise at NYU, as well as the experience of studying medicine in the heart of New York City.

At MTAnalyics we focus on increasing statistical power to improve the detection of weak association signals between variables. By contrast to data mining, we are using statistical tools that allow us to provide power and p-values in our analysis. In other words, we are specific alike classic statistics and sensitive as data mining.

For clinical trials, we significantly reduce the sample size while keeping the same power. Fundamentally, you will be able to decrease your sample size by 30% while keeping the same p-value, the same statistical power. Obvious main consequences: gain of time, of money, resources etc…

Our work addresses these challenges and aims at providing rationale to design and perform statistical analysis when large amount of data are available. We are not competing with the companies allowing to hire patients faster. We come into play before the design of the trial even started to allow for the design of a trial to include a reduced sample size. We focus in particular on increasing statistical power in order to reduce sample size or improving the detection of weak association between variables by leveraging all available information.

In big data, we provide insights into data sets, predict outcomes, increase the strengths of the models used to explain an outcome based on the analysis of a dataset. Again, the basis of our approach is to improve the detection of weak signals.

Any classical approach is able to detect a strong signal, but when an outcome is not explained (or associated) to one major or a few big variables but by a multiple of weak signals, you need a model to link and find these weak signals, in order to explain a maximum of your outcome.

With our approach, we are able to explain significantly more of the outcome, by reinforcing the models, by finding weak associations hidden in the data sets and missed by the other approaches. In other words, we detect associations that others cannot.

Fosters, develops and commercializes healthcare and life sciences technology.

NovoDux is developing the next generation of innovative and unique compounds for a variety of human diseases using its patented multi-targeted technology. The  compounds enable therapeutic applications for different human diseases in the fields of oncology, infectious diseases and neurology.